07/31/2025 – 10:03 PM
LAKE FOREST, Calif.–(BUSINESS WIRE)– STAAR Surgical Company (NASDAQ: STAA), a global frontrunner in phakic IOLs, specifically the EVO family of Implantable Collamer® Lenses (EVO ICL™) designed for vision correction, is set to unveil its financial performance for the second quarter, concluding on June 27, 2025. The announcement will be made on Wednesday, August 6, 2025, after the market bell. Investors and analysts, take note: STAAR will also host an earnings call and webcast at 4:30 p.m. ET to dissect the numbers and shed light on the company’s strategic progress.
Event: STAAR Surgical 2Q 2025 Financial Results Webcast
Date: Wednesday, August 6, 2025
Time: 4:30 p.m. ET
Location: https://registrations.events/direct/IDX8578398
For real-time access, including pre-registration, tune into the live webcast via the provided link. Alternatively, head to the “Investors” section of STAAR’s website at https://investors.staar.com/. Missed the live broadcast? A replay will be available at the same location for at least 90 days.
About STAAR Surgical
STAAR Surgical (NASDAQ: STAA) isn’t just another player in the vision correction space; it’s the global leader in implantable phakic intraocular lenses, offering a compelling solution to diminish or eliminate the need for spectacles or contact lenses. With a legacy dating back to 1982, STAAR has maintained an unwavering focus on ophthalmic surgery. For three decades, the company has spearheaded the design, development, manufacturing, and marketing of advanced Implantable Collamer® Lenses (ICLs), leveraging its proprietary biocompatible Collamer material. Clinical data supports STAAR ICLs as a safe, long-term vision correction method that preserves corneal tissue and the eye’s natural crystalline lens. The EVO ICL™ product line promises visual freedom through a quick, minimally invasive procedure. To date, STAAR has distributed over 3 million ICLs spanning more than 75 countries. Headquartered in Lake Forest, California, the company’s operational footprint includes research, development, manufacturing, and packaging facilities in both California and Switzerland. For further insights into ICL technology, explore www.EVOICL.com. Learn more about STAAR at www.staar.com.
The company is using its website to disseminate important non-public information, ensuring compliance with Regulation FD. Access these disclosures in the ‘Investor Relations’ section at investors.staar.com. Investors should monitor this section closely, alongside press releases, SEC filings, public conference calls and webcasts. Sign up for email alerts and company updates in the News & Alerts section at https://investors.staar.com/.
Source: STAAR Surgical Company
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/6140.html
